CLEVELAND BIOLABS, INC. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States.
Its products in development include Protectans, the modified proteins of microbes that protect cells from apoptosis; and Curaxins, the small molecules that destroy tumor cells by simultaneously targeting
two regulators of apoptosis.
The company's lead product candidates, CBLB502 showed radioprotective efficacy as a single therapy in non-human primates; and Protectan CBLB612 provided protection in a mouse model from lethal
hematopoietic-induced radiation sickness. In addition, it is developing Curaxin CBLC102, a Phase II clinical trial product, for the treatment of hormone refractory prostate cancer. CLEVELAND BIOLABS
has a collaboration agreement with Cleveland Clinic Foundation to use Cleveland Clinic's research base underlying the company's therapeutic platform; strategic research partnership with Roswell Park
Cancer Institute to develop its cancer and radioprotectant drug candidates; and strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds, and jointly manage
the development and commercialization of compounds arising from selected projects. The company was founded in 2003 and is headquartered in Buffalo, New York.